{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:50:10Z","timestamp":1792227010977,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41582-025-01144-0","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:03:57Z","timestamp":1758110637000},"page":"661-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The multiple sclerosis prodrome: insights into how and when disease starts"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1144_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1144_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00270-4","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4 (2025).","journal-title":"Lancet Neurol."},{"key":"1144_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41582-022-00686-x","volume":"18","author":"RA Marrie","year":"2022","unstructured":"Marrie, R. A. et al. From the prodromal stage of multiple sclerosis to disease prevention. Nat. Rev. Neurol. 18, 559\u2013572 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1144_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24635","volume":"8","author":"M Ruiz-Alguer\u00f3","year":"2025","unstructured":"Ruiz-Alguer\u00f3, M. et al. Health care use before multiple sclerosis symptom onset. JAMA Netw. Open 8, e2524635 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1144_CR5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/acn3.70092","volume":"12","author":"H Tremlett","year":"2025","unstructured":"Tremlett, H. et al. Phenotyping healthcare use 2\u20133 decades before the first multiple sclerosis demyelinating event. Ann. Clin. Transl. Neurol. 12, 1585\u20131594 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1144_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/13524585241291471","volume":"31","author":"C Lebrun-Frenay","year":"2025","unstructured":"Lebrun-Frenay, C. et al. Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome. Mult. Scler. 31, 184\u2013196 (2025).","journal-title":"Mult. Scler."},{"key":"1144_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(17)30076-5","volume":"16","author":"JMA Wijnands","year":"2017","unstructured":"Wijnands, J. M. A. et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 16, 445\u2013451 (2017).","journal-title":"Lancet Neurol."},{"key":"1144_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335279","author":"A Manouchehrinia","year":"2025","unstructured":"Manouchehrinia, A. et al. Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset \u2014 a matched cohort study. J. Neurol. Neurosurg. Psychiatry https:\/\/doi.org\/10.1136\/jnnp-2024-335279 (2025).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1144_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ana.24769","volume":"80","author":"M Cortese","year":"2016","unstructured":"Cortese, M. et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann. Neurol. 80, 616\u2013624 (2016).","journal-title":"Ann. Neurol."},{"key":"1144_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","volume":"77","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58\u201364 (2020).","journal-title":"JAMA Neurol."},{"key":"1144_CR11","first-page":"325","volume":"95","author":"D Jons","year":"2024","unstructured":"Jons, D. et al. Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage. J. Neurol. Neurosurg. Psychiatry 95, 325\u2013332 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1144_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200044","volume":"10","author":"M Rival","year":"2022","unstructured":"Rival, M. et al. Neurofilament light chain levels are predictive of clinical conversion in radiologically isolated syndrome. Neurol. Neuroimmunol. Neuroinflamm. 10, e200044 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1144_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/mds.27281","volume":"33","author":"P Mahlknecht","year":"2018","unstructured":"Mahlknecht, P. et al. Performance of the Movement Disorders Society criteria for prodromal Parkinson\u2019s disease: a population-based 10-year study. Mov. Disord. 33, 405\u2013413 (2018).","journal-title":"Mov. Disord."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01144-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01144-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01144-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:03:29Z","timestamp":1764248609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01144-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01144-0","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"17 September 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the past five years, H.T. has had travel expenses or registration fees prepaid or reimbursed to present at Continuing Medical Education conferences or attend meetings (for example, as a member of the International Advisory Committee on Clinical Trials in Multiple Sclerosis) from the Consortium of MS Centres (2023), the Canadian Neurological Sciences Federation (2023), National MS Society (2022-25), ECTRIMS and\/or ACTRIMS (2017-2025), MS Canada (2023, 2025) and the American Academy of Neurology (2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by H.T.\u2019s research group.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}